Confo Therapeutics utilizes a proprietary technology to stabilize functional conformations of G protein-coupled receptors (GPCRs), enabling the identification of previously inaccessible drug targets. The company focuses on developing novel GPCR modulators to provide disease-modifying treatments for patients with severe illnesses that currently lack effective therapies.
Funding
$65.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
G protein-coupled receptors (GPCRs) are challenging drug targets due to their inherent instability and conformational flexibility, which limits the discovery of selective and effective modulators. Many severe illnesses lack effective therapies because the relevant GPCR targets are inaccessible to traditional drug discovery methods.
Solution
Confo Therapeutics has developed a technology to stabilize functional conformations of GPCRs, enabling the identification of previously inaccessible drug targets. This platform allows for structure-based drug design and the discovery of novel GPCR modulators. By stabilizing GPCRs in specific functional states, Confo Therapeutics can identify compounds that selectively modulate receptor activity, leading to more effective and targeted therapies. The company's approach aims to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel drug targets and innovative approaches to GPCR modulation, as well as patients with severe illnesses lacking effective therapies.
Features
- Proprietary technology to stabilize functional conformations of GPCRs
- Structure-based drug design for GPCR modulators
- Identification of previously inaccessible drug targets
- Focus on disease-modifying treatments for severe illnesses
- Growing pipeline of novel drug candidates